Genzyme Corporation

Gloria Matthews

John L Kane, Jr

Markus Metz

Andrew Scholte

Michael Kothe

Jinyu Liu

Clark Qun Pan

Huawei Qiu

James E Stefano

John L Kane

Michael O'Callaghan

Jr Kane John L

Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Tropomyosin-related kinase (trk) inhibitors

Tropomyosin-related kinase (Trk) inhibitors

Tropomyosin-related kinase (TRK) inhibitors

The invention provides compositions and methods for treating a disease or disorder associate with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof.

Nucleotide sequences encoding VEGF antagonist compositions of FLT-1 and uses thereof

The invention provides compositions and methods for treating a disease or disorder associated with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof.

VEGF antagonist compositions and uses thereof

Growing community of inventors

Boylston, MA, United States of America

Gloria Matthews